Unlocking the Potential of ELP5: A novel Protein Target for Cancer Treatment

Target Name: ELP5

NCBI ID: G23587

ELP5

Unlocking the Potential of ELP5: A novel Protein Target for Cancer Treatment

Introduction

Elongator complex protein 5 (ELP5) is a unique protein that has caught the attention of researchers due to its potential in cancer treatment. ELP5 is a protein that is expressed in various tissues and cells of the body, including the brain, heart, and blood vessels. Its functions include cell adhesion, migration, and invasion, which are critical processes in the development and progression of cancer. Therefore, targeting ELP5 has the potential to offer new and effective treatments for various types of cancer.

During this article, we will explore the biology of ELP5, its potential as a drug target, and the ongoing research in this field. We will discuss the current understanding of ELP5's role in cancer progression and the potential strategies for its targeting.

The Biology of ELP5

ELP5 is a 21-kDa protein that is composed of 118 amino acid residues. It is characterized by a long extracellular domain that contains a unique farnesylated cysteine 鈥嬧?媟esidue, which is involved in protein-protein interactions and modulation of protein stability. ELP5 is also known for its role in cell adhesion and migration, as well as its involvement in the regulation of cell cycle progression and apoptosis.

In cancer, ELP5 has been observed to promote the growth and survival of various types of cancer cells. For example, ELP5 has been shown to promote the growth of breast cancer cells in a xenograft model and to contribute to their enhanced metastatic potential. Similarly, ELP5 has also been shown to promote the growth and survival of lung cancer cells in a xenograft model, and to enhance their ability to invade the surrounding tissue.

The Potential of ELP5 as a Drug Target

The potential of ELP5 as a drug target is based on its involvement in various signaling pathways that are associated with cancer progression. One of the main mechanisms by which ELP5 contributes to cancer progression is its role in the regulation of cell adhesion and migration. ELP5 has has been shown to play a critical role in the regulation of cell-cell adhesion by interacting with various adhesion molecules, including cadherins and immunoglobulin adhesion molecules.

In addition to its role in cell adhesion and migration, ELP5 has also been implicated in the regulation of cell cycle progression and apoptosis. ELP5 has been shown to contribute to the regulation of cell cycle progression by interacting with the protein p21. Additionally , ELP5 has also been shown to play a critical role in the regulation of apoptosis by interacting with the protein Bcl-2.

Opportunities for Targeting ELP5

The potential of ELP5 as a drug target is based on its involvement in various signaling pathways that are associated with cancer progression. Therefore, several strategies have been proposed to target ELP5 and its downstream targets.

One of the main strategies is the use of small molecules that can inhibit ELP5's activity. For example, several studies have shown that inhibitors of the protein kinase A (PKA) can effectively inhibit ELP5's activity, leading to the collapse of its signaling pathway and a decrease in cell proliferation. Additionally, inhibitors of the protein tyrosine kinase (PTK) can also be used to target ELP5, as they have been shown to inhibit the activity of ELP5 in cell adhesion and migration.

Another strategy is the use of monoclonal antibodies (mAbs) that can specifically target ELP5. ELP5 has been shown to be a good candidate for mAbs due to its high expression level and its unique farnesylated cysteine 鈥嬧?媟esidue, which is involved in protein-protein interactions and modulation of protein stability. mAbs against ELP5 have been shown to be effective in preclinical studies in targeting ELP5 and its downstream targets, leading to a decrease in

Protein Name: Elongator Acetyltransferase Complex Subunit 5

Functions: Component of the elongator complex which is required for multiple tRNA modifications, including mcm5U (5-methoxycarbonylmethyl uridine), mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine), and ncm5U (5-carbamoylmethyl uridine) (PubMed:29332244). The elongator complex catalyzes formation of carboxymethyluridine in the wobble base at position 34 in tRNAs (PubMed:29332244). Involved in cell migration (By similarity)

The "ELP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets